The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

MTX3  -  metaxin 3

Homo sapiens

Synonyms: Metaxin-3
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on MTX3

  • PATIENTS AND METHODS: Treatment consisted of two cycles of MBVP (MTX 3 g/m2 days 1 and 15, teniposide 100 mg/m2 days 2 and 3, carmustine 100 mg/m2 day 4, methylprednisolone 60 mg/m2 days 1 to 5, and two intrathecal injections of MTX 15 mg, cytarabine 40 mg, and hydrocortisone 25 mg) followed by 40 Gy of RT [1].
  • RESULTS: At week 54, the median percentage of American College of Rheumatology improvement (ACR-N) was higher for the MTX-3 mg/kg infliximab and MTX-6 mg/kg infliximab groups than for the MTX-placebo group (38.9% and 46.7% versus 26.4%, respectively; P < 0.001 for both comparisons) [2].
  • Patients in the MTX-3 mg/kg infliximab and MTX-6 mg/kg infliximab groups also showed less radiographic progression than those receiving MTX alone (mean +/- SD changes in van der Heijde modification of the total Sharp score at week 54: 0.4 +/- 5.8 and 0.5 +/- 5.6 versus 3.7 +/- 9.6, respectively; P < 0.001 for each comparison) [2].
  • Thirteen patients (1996-1999; median age 54 years) received two courses of vincristine 1.4 mg/m2 day 1, MTX 3 g/m2 days 3 and 10 and procarbazine 100 mg/m2 days 1-14 every 4 weeks [3].
  • We have studied the tumorigenicity of a CCRF-CEM-derived cell line (CEM/MTX-3) resistant to MTX [4].

Biological context of MTX3

  • Although biochemical mechanisms are not yet delineated, this remodeled chromosome could be related to the loss of tumorigenicity in CEM/MTX-3 cells [4].
  • At 6 weeks of gestation, she took 2.5 mg of MTX 3 times a day for 7 days [5].

Anatomical context of MTX3

  • Cytogenetic analysis revealed that the CEM/MTX-3 karyotype contained a unique and complex translocation marker chromosome that was not observed in the CEM cell line and which involved chromosomal breakpoints at bands 11p14, 22p11, and 22p13 [4].

Associations of MTX3 with chemical compounds

  • Because tumorigenicity could have been related to intracellular folate levels, we cultured CEM and CEM/MTX-3 cells in folate-rich and folate-deprived media [4].
  • Instead, the resistance in CEM/MTX-3 cells appeared to be due largely to decreased methotrexate accumulation [4].

Other interactions of MTX3


  1. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. Poortmans, P.M., Kluin-Nelemans, H.C., Haaxma-Reiche, H., Van't Veer, M., Hansen, M., Soubeyran, P., Taphoorn, M., Thomas, J., Van den Bent, M., Fickers, M., Van Imhoff, G., Rozewicz, C., Teodorovic, I., van Glabbeke, M. J. Clin. Oncol. (2003) [Pubmed]
  2. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., Keystone, E., Schiff, M., Kalden, J.R., Wang, B., Dewoody, K., Weiss, R., Baker, D. Arthritis Rheum. (2004) [Pubmed]
  3. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients. Ferreri, A.J., Reni, M., Dell'Oro, S., Ciceri, F., Bernardi, M., Camba, L., Ponzoni, M., Terreni, M.R., Tomirotti, M., Spina, M., Villa, E. Oncology (2001) [Pubmed]
  4. Loss of tumorigenicity in a methotrexate-resistant human leukemia cell line. Hill, A.B., Trent, J.M., Thompson, F.H., Danks, M.K., Beck, W.T. Cancer Genet. Cytogenet. (1993) [Pubmed]
  5. A case of methotrexate embryopathy with holoprosencephaly, expanding the phenotype. Seidahmed, M.Z., Shaheed, M.M., Abdulbasit, O.B., Al Dohami, H., Babiker, M., Abdullah, M.A., Abomelha, A.M. Birth Defects Res. Part A Clin. Mol. Teratol. (2006) [Pubmed]
  6. The structure and cytochemistry of the neurosecretory cells in Ocypoda platytarsis Milne Edwards (Crustacea: Brachyura). Babu, D.E., Shyamasundari, K., Rao, K.H. Zeitschrift für mikroskopisch-anatomische Forschung. (1979) [Pubmed]
WikiGenes - Universities